Replimune (REPL) EPS (Weighted Average and Diluted) (2020 - 2025)
Replimune's (REPL) quarterly EPS (Weighted Average and Diluted) came in at -$0.77 in Q4 2025, up 2.53% year-on-year from -$0.75 in Q4 2024, and up 14.44% quarter-over-quarter from -$0.9 in Q3 2025.
Replimune (REPL) EPS (Weighted Average and Diluted) (2020 - 2025) Analysis & Trends
Replimune has disclosed EPS (Weighted Average and Diluted) across 6 years of filings, most recently posting -$0.77 for Q4 2025.
- EPS (Weighted Average and Diluted) for Q4 2025 came in at -$0.77, up 2.53% year-over-year; the trailing twelve-month figure through Dec 2025 was -$3.44 (down 12.05% YoY), and the FY2025 annual result was -$3.07, up 5.25% from the prior year.
- EPS (Weighted Average and Diluted) came in at -$0.77 for Q4 2025 at Replimune, up from -$0.9 in the prior quarter.
- In the past five years, EPS (Weighted Average and Diluted) ranged from a high of -$0.41 in Q1 2021 to a low of -$0.95 in Q2 2025.
- The 5-year median for EPS (Weighted Average and Diluted) is -$0.77 (2023), against an average of -$0.73.
- Across the five-year window, EPS (Weighted Average and Diluted) tumbled 47.17% in 2022 and increased 24.44% in 2024, its largest moves.
- Replimune's EPS (Weighted Average and Diluted) stood at -$0.57 in 2021, then decreased by 21.05% to -$0.69 in 2022, then retreated by 11.59% to -$0.77 in 2023, then retreated by 2.6% to -$0.79 in 2024, then rose by 2.53% to -$0.77 in 2025.
- The last three EPS (Weighted Average and Diluted) figures came in at -$0.77 (Q4 2025), -$0.9 (Q3 2025), and -$0.95 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | 0.68 |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | 3.06 |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | 3,086.42 |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | 0.00 |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | 0.00 |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 4.02 |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | -0.61 |
| 10 | Replimune | 780.01 Mn | 510.88 Mn | - | -0.77 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -0.77 |
| Sep 30, 2025 | -0.90 |
| Jun 30, 2025 | -0.95 |
| Mar 31, 2025 | -0.82 |
| Dec 31, 2024 | -0.79 |
| Sep 30, 2024 | -0.68 |
| Jun 30, 2024 | -0.78 |
| Mar 31, 2024 | -0.82 |
| Dec 31, 2023 | -0.77 |
| Sep 30, 2023 | -0.90 |
| Jun 30, 2023 | -0.75 |
| Mar 31, 2023 | -0.74 |
| Dec 31, 2022 | -0.69 |
| Sep 30, 2022 | -0.79 |
| Jun 30, 2022 | -0.78 |
| Mar 31, 2022 | -0.60 |
| Dec 31, 2021 | -0.57 |
| Sep 30, 2021 | -0.56 |
| Jun 30, 2021 | -0.53 |
| Mar 31, 2021 | -0.41 |